Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY
Management reported a NAV of
The unaudited operating division reports the following highlights from its financial performance:
- Revenue increased 31.8% Year on Year for 2023 versus 2022
- Revenue in the first 2 months of 2024 has increased 229.1% Year on Year versus 2023
- Number of Kits sold for our Diagnostic System rose 36.2% Year on Year for 2023 versus 2022
- Kit revenue in the first 2 months of 2024 has increased 95.7% Year on Year versus 2023
- 12 New Accounts launched in 2023, combination of sales, rentals, and ezBVA Lab services
- 6 New Accounts in the first 2 months of 2024, combination of sales, lease, and ezBVA Lab services
The operating company increased additional revenues to its commercial operations from the second half of 2023 with contracts from the
“We are pleased with our strong financial performance for fiscal 2023 driven by a combination of sold, leased, placed devices for commercial and research uses, and new lab services accounts, with eighteen new clients added. We have seen tremendous momentum coming into 2024 which is especially exciting as we get set to launch our newest point-of-care system when cleared by the FDA.”
Management has released more details from its operating division in a shareholder letter and intends to hold a shareholder meeting for further discussion of results.
About
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the
Investor Relations Contact:
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
Source:
2024 GlobeNewswire, Inc., source